This trial will measure the level of neuroinflammation in the brains of people with Parkinson's disease compared to healthy controls, using a PET scan with the tracer [18F]DPA-714.
2 Primary · 0 Secondary · Reporting Duration: 2 years
Experimental Treatment
20 Total Participants · 2 Treatment Groups
Primary Treatment: DPA-714-PET/MRI · No Placebo Group · Phase 1 & 2
Participation is compensated
You will be compensated for participating in this trial.
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: